Bioventix PLC (GB:BVXP)
LSE:BVXP
BVXP Stock Chart & Stats
1800.00 p
56.00 p(1.70%)
At close: 4:00 PM EST
1800.00 p
56.00 p(1.70%)
Day’s Range― - ―
52-Week Range1,300.00 p - 3,020.00 p
Previous CloseN/A
Volume24.00
Average Volume (3M)7.85K
Market Cap
£71.84M
Enterprise Value66.76M
Total Cash (Recent Filing)£5.08M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)18.9
Beta0.30
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield8.33%
Share Statistics
EPS (TTM)0.72
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.93
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.36
Revenue Forecast (FY)£12.50M
Bulls Say, Bears Say
Bulls Say
High Profit MarginsBioventix’s exceptionally high gross and net margins indicate structural pricing power from proprietary monoclonal antibodies and low variable costs. These margins support durable cash generation, fund dividends/R&D, and provide a buffer versus cyclical test volumes, sustaining long-term profitability even with revenue variability.
Strong Cash ConversionFree cash flow that closely mirrors net income demonstrates high-quality earnings and liquidity conversion. Reliable FCF supports recurring dividends, funds selective reinvestment or licensing activities, and reduces dependence on external financing — a durable strength for multi-year stability even if growth slows.
Debt-free Balance Sheet & High ROEA zero-debt balance sheet reduces financial risk and preserves strategic optionality for investments or shareholder distributions. Extremely high ROE reflects efficient use of equity and strong earnings power, enabling long-term capital returns and resilience to industry headwinds without leverage-driven vulnerability.
Bears Say
2025 Revenue And FCF SlowdownA clear 2025 decline in both revenue and free cash flow signals weakening operating momentum. Persistent top-line softness can erode royalty growth, limit reinvestment, pressure dividend sustainability, and make long-term planning harder despite strong margins and cash conversion history.
Negative Recent Growth MetricsNegative revenue and EPS growth rates underscore that operating performance has turned down. Over multiple quarters this pattern can indicate demand pressure or lost placements, increasing the risk that one-off weakness becomes a longer-term trend and reducing predictability of royalty income streams.
Dependence On Design‑ins With Large IVD CustomersBusiness model concentration on successful design-ins creates binary, lumpy revenue outcomes tied to a few large customers and platform approvals. Loss of a design-in, slower customer adoption, or changes in partner strategies can materially reduce recurring royalties and make growth outcomes uneven.
Bioventix News
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 1300.00 p and its highest was 3020.00 p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £71.84M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Mar 30, 2026 which is today.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Oct 27, 2025. The company reported 0.72 p earnings per share for the quarter, missing the consensus estimate of 0.78 p by -0.06 p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Semiannually dividend of 80 p which represents an annual dividend yield of 8.33%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.72 p in its last earnings report, missing expectations of 0.78 p. Following the earnings report the stock price went down -15.699%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:BVXP Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth £53.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.51%
12-Months-Change
Fundamentals
Return on Equity
66.44%
Trailing 12-Months
Asset Growth
-6.32%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---